“My friend said it was good LSD”: A suicide attempt following analytically confirmed 25I-NBOMe ingestion

Journal of Psychoactive Drugs

Volumn 46, Issue 5, 2014, Pages 379-382

  Suzuki, Joji ^a   Poklis, Justin L ^b   Poklis, Alphonse ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Hallucinogens; LSD; NBOMe; Psychedelics

Indexed keywords

4 IODO 2,5 DIMETHOXY N (2 METHOXYBENZYL) PHENYLETHYLAMINE; LYSERGIDE; PSYCHEDELIC AGENT; UNCLASSIFIED DRUG; 2-(4-IODO-2,5-DIMETHOXYPHENYL)-N-(2-METHOXYBENZYL)ETHANAMINE; HOMOVERATRYLAMINE;

ANXIETY; ARTICLE; BLOOD ANALYSIS; BRONCHOSCOPY; CANNABIS USE; CHEST TUBE; ENDOSCOPY; EUPHORIA; HEART RATE; NECK INJURY; OXYGEN SATURATION; PLEURA EFFUSION; PNEUMOTHORAX; SALVIA DIVINORUM; STAB WOUND; SUICIDE ATTEMPT; TACHYCARDIA; THORAX INJURY; VISUAL HALLUCINATION; ADOLESCENT; ANALOGS AND DERIVATIVES; CASE REPORT; HUMAN; MALE;

ADOLESCENT; DIMETHOXYPHENYLETHYLAMINE; HALLUCINOGENS; HUMANS; LYSERGIC ACID DIETHYLAMIDE; MALE; SUICIDE, ATTEMPTED;

EID: 84922479825     PISSN: 02791072     EISSN: 21599777     Source Type: Journal    
DOI: 10.1080/02791072.2014.960111     Document Type: Article

References (14)

1. Braden, M.R.; Parrish, J.C.; Naylor, J.C. & Nichols, D.E. 2006. Molecular interaction of serotonin 5-HT2A receptor residues Phe339(6.51) and Phe340(6.52) with superpotent N-benzyl phenethylamine agonists. Molecular Pharmacology 70 (6): 1956–64.
2. Caldicott, D.G.E.; Bright, S.J. & Barratt, M.J. 2013. NBOMe: A very different kettle of fish. The Medical Journal of Australia 199 (5): 322–23.
3. Erowid, E. & Erowid, F. 2013. Spotlight on NBOMes: Potent psychedelic issues. Available at: http://www.erowid.org/chemicals/nbome/nbome_article1.shtml.
4. Halberstadt, A.L. & Geyer, M.A. 2014. Effects of the hallucinogen 2,5- dimethoxy-4-iodophenethylamine (2C-I) and superpotent N-benzyl derivatives on the head twitch response. Neuropharmacology 77 (February): 200–207.
5. Hill, S.L.; Doris, T.; Gurung, S.; Katebe, S.; Lomas, A.; Dunn, M.; Blain P. & Thomas, S.H.L. 2013. Severe clinical toxicity associated with analytically confirmed recreational use of 25I-NBOMe: Case series. Clinical Toxicology 51 (6): 487–92.
6. Lawn, W., Barratt, M., Williams, M., Horne, A. & Winstock, A. 2014. The NBOMe hallucinogenic drug series: Patterns of use, characteristics of users and self-reported effects in a large international sample.” Journal of Psychopharmacology 28 (8): 780–788.
7. Ninnemann, A. & Stuart, G.L. 2013. The NBOMe series: A novel, dangerous group of hallucinogenic drugs. Journal of Studies on Alcohol and Drugs 74 (6): 977–78.
8. Passie, T.; Halpern, J.H.; Stichtenoth, D.O.; Emrich, H.M. & Hintzen, A. 2008. The pharmacology of lysergic acid diethylamide: A review. CNS Neuroscience & Therapeutics 14 (4): 295–314.
9. Poklis, J.L.; Charles, J.; Wolf, C.E. & Poklis, A. 2013. High-performance liquid chromatography tandem mass spectrometry method for the determination of 2CC-NBOMe and 25I-NBOMe in human serum. Biomedical Chromatography: BMC 27 (12): 1794–1800.
10. Poklis, J.L.; Devers, K.G.; Arbefeville, E.F.; Pearson, J.M.; Houston, E. & Poklis, A. 2014. Postmortem detection of 25I-NBOMe [2-(4-iodo- 2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine] in fluids and tissues determined by high performance liquid chromatography with tandem mass spectrometry from a traumatic death. Forensic Science International 234 (January): e14–20.
11. Rose, S.R.; Poklis, J.L. & Poklis, A. 2013. A case of 25I-NBOMe (25-I) intoxication: A new potent 5-HT2A agonist designer drug. Clinical Toxicology 51 (3): 174–77.
12. Stellpflug, S.J., Kealey, S.E., Hegarty, C.B. & Janis, G.C. 2013. 2-(4-iodo- 2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine (25I-NBOMe): Clinical case with unique confirmatory testing. Journal of Medical Toxicology: Official Journal of the American College of Medical Toxicology 10 (1): 45–50.
13. Walterscheid, J.P.; Phillips, G.T.; Lopez, A.E.; Gonsoulin, M.L.; Chen, H.-H. & Sanchez, L.A. 2014. Pathological findings in 2 cases of fatal 25I-NBOMe toxicity. The American Journal of Forensic Medicine and Pathology 35 (1): 20–25.
14. Zuba, D.; Sekuła, K. & Buczek, A. 2013. 25C-NBOMe: New potent hallucinogenic substance identified on the drug market. Forensic Science International 227 (1-3): 7–14.